NASDAQ:BOLD - Audentes Therapeutics Stock Price, Forecast & News

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same period in the previous year, the firm posted ($0.97) earnings per share. View Audentes Therapeutics' Earnings History.

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Audentes Therapeutics.

16 Wall Street analysts have issued 12-month price objectives for Audentes Therapeutics' stock. Their forecasts range from $10.00 to $60.00. On average, they anticipate Audentes Therapeutics' share price to reach $50.54 in the next year. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Audentes Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 14 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.

Media headlines about BOLD stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Audentes Therapeutics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Audentes Therapeutics.

Some companies that are related to Audentes Therapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer LP Unit (ET), Crispr Therapeutics (CRSP), Clovis Oncology (CLVS), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Intel (INTC), Ionis Pharmaceuticals (IONS), Myriad Genetics (MYGN) and bluebird bio (BLUE).

(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Audentes Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Magnetar Financial LLC (3.45%), CNH Partners LLC (2.94%), State Street Corp (2.83%), Partner Fund Management L.P. (2.66%), Farallon Capital Management LLC (2.57%) and RA Capital Management L.P. (1.95%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.

BOLD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Partner Fund Management L.P., Jennison Associates LLC, State Street Corp, UBS Asset Management Americas Inc., Candriam Luxembourg S.C.A., Spark Investment Management LLC and Rafferty Asset Management LLC. Company insiders that have sold Audentes Therapeutics company stock in the last year include Louis G Lange, Matthew R Patterson and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

BOLD stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, CNH Partners LLC, Farallon Capital Management LLC, RA Capital Management L.P., Bank of America Corp DE, Syquant Capital Sas, Gabelli Funds LLC and ARP Americas LP. View Insider Buying and Selling for Audentes Therapeutics.

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BOLD stock can currently be purchased for approximately $59.97.

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.View Additional Information About Audentes Therapeutics.

The official website for Audentes Therapeutics is http://www.audentestx.com/.

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]